Patient and sample characteristics
| Overall | Lung cancer | Melanoma | SCCHN | UC | |
| Patients, n (%)* | |||||
| Total | 55 652 (100) | 21 224 (38) | 678 (1) | 270 (<1) | 223 (<1) |
| PD-L1 tests by biopsy site, n (%)† | |||||
| Any | 62 180 (100) | 24 428 (100) | 754 (100) | 305 (100) | 254 (100) |
| Lung | 33 168 (53) | 18 239 (75) | 61 (8) | 49 (16) | 18 (7) |
| Lymph node | 6154 (10) | 1715 (7) | 140 (19) | 30 (10) | 19 (7) |
| Liver | 2933 (5) | 465 (2) | 31 (4) | 7 (2) | 5 (2) |
| Bone‡ | 2812 (5) | 685 (3) | 20 (3) | 5 (2) | 9 (4) |
| Pleural fluid‡ | 2071 (3) | 642 (3) | 2 (<1) | 2 (1) | 5 (2) |
| Brain | 1931 (3) | 351 (1) | 31 (4) | 4 (1) | 2 (1) |
| Head and neck | 1099 (2) | 176 (1) | 48 (6) | 126 (41) | 2 (1) |
| Skin | 386 (1) | 26 (<1) | 114 (15) | 5 (2) | 0 |
| Bladder | 308 (<1) | 2 (<1) | 0 | 0 | 153 (60) |
| Other§ | 11 318 (18) | 2127 (9) | 307 (41) | 77 (25) | 41 (16) |
| PD-L1 tests performed, n (%) | |||||
| All tests | 62 180 (100) | 24 428 (100) | 754 (100) | 305 (100) | 254 (100) |
| 28-8 tests | 6081 (10) | 2437 (10) | 401 (53) | 66 (22) | 24 (9) |
| 22C3 tests | 55 217 (89) | 21 709 (89) | 349 (46) | 235 (77) | 133 (52) |
| SP142 tests | 882 (1) | 282 (1) | 4 (1) | 4 (1) | 97 (38) |
| PD-L1 expression on tumour cells, n (% patients) | |||||
| Patients with a single uniform value for the 28-8 or 22C3 assays¶ | 51 654 (100) | 19 558 (100) | 634 (100) | 248 (100) | 134 (100) |
| 0% | 20 503 (40) | 6975 (36) | 291 (46) | 99 (40) | 64 (48) |
| 1%–4% | 4099 (8) | 1430 (7) | 65 (10) | 15 (6) | 10 (7) |
| 5%–49% | 11 899 (23) | 4619 (24) | 190 (30) | 65 (26) | 31 (23) |
| ≥50% | 15 153 (29) | 6534 (33) | 88 (14) | 69 (28) | 29 (22) |
Numbers in bold denote biopsies from primary tumour sites.
*A total of 33 257 patients had missing diagnostic information or a diagnosis other than lung cancer, melanoma, SCCHN or UC.
†Biopsy sites comprising ≥3% of biopsies in the total study population or tumour type subgroups.
‡The 28-8 and 22C3 assays have not been validated for use with fine-needle aspirates, cytology specimens or decalcified tissue.
§Biopsy sites comprising <3% of biopsies in the total study population or tumour-type subgroups were adrenal, breast, colon, colorectal, diaphragm, eye, gallbladder, gastric, kidney, mediastinal, oesophagus, ovary, pancreas, pericardial, pericardial fluid, prostate, rectum, soft tissue, trachea and other non-specified sites.
¶Patients with a single test result or two or more identical 28-8 or 22C3 assay results.
PD-L1, programmed death ligand 1; SCCHN, squamous cell carcinoma of the head and neck; UC, urothelial carcinoma.